Press-release for stocks related to therapeutics

Prices are updated after-hours

tags : Therapeutics crawled date : 2023 - 01 - 25

save search

Inhibikase Therapeutics Announces $10 Million Concurrent Registered Direct Offering and Private Placement Priced at a Premium to Market Under Nasdaq Rules
Published: 2023-01-25 (Crawled : 23:00) - biospace.com/
IKT | $1.57 14.6% 12.74% 78K

Health Technology

| -71.06% | O: 9.85% H: 15.78% C: -13.97%
offering nasdaq therapeutics direct market

Global Psoriasis Therapeutics Market Report to 2031 - Featuring Abbvie, Amgen, Bausch Health, LEO Pharma and Novan Among Others
Published: 2023-01-25 (Crawled : 21:00) - prnewswire.com
NVSEF | News | $95.11 6.88% 490

Health Technology

| 26.59% | O: -1.1% H: 0.0% C: 0.0%
VTRS | News A | $11.36 0.98% 0.97% 4.7M

Health Technology

| -2.41% | O: -0.69% H: 0.87% C: 0.69%
NVS | News | $97.28 2.27% 0.31% 3.7M

Health Technology

| 6.52% | O: -1.97% H: 0.11% C: -1.25%
LLY | News | $745.69 1.96% -0.16% 2M

Health Technology

| 111.32% | O: 0.36% H: 0.34% C: -0.85%
BHC | $8.53 0.95% 0.0% 4M

Health Technology

| 1.79% | O: 1.91% H: 3.28% C: -0.23%
ABBV | News | $169.54 0.98% -0.91% 4.1M

Health Technology

| 14.72% | O: 0.09% H: 0.53% C: -0.35%
AMGN | News | $273.69 0.66% 0.65% 2.5M

Health Technology

| 6.63% | O: 0.0% H: 0.06% C: -0.65%
leo pharma global report therapeutics psoriasis market

Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy
Published: 2023-01-25 (Crawled : 15:20) - biospace.com/
HOTH | $1.15 1.2% 29K

Health Technology

| -76.67% | O: -1.76% H: 2.79% C: 2.79%
trial therapeutics therapy cancer growth

Sling Therapeutics Announces Appointment of Jeffrey Kent, M.D., FACG, FACP, as Chief Medical Officer
Published: 2023-01-25 (Crawled : 15:00) - biospace.com/
ABT | News | $107.59 0.49% -0.09% 3.8M

Health Technology

| -4.39% | O: -2.25% H: 2.04% C: 0.91%
medical therapeutics

ZyVersa Therapeutics to Present at BIO CEO & Investor Conference
Published: 2023-01-25 (Crawled : 15:00) - globenewswire.com
ZVSA | $0.5605 -2.49% -2.55% 150K

| -76.17% | O: -2.13% H: 2.17% C: -8.26%
ceo conference therapeutics

Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
Published: 2023-01-25 (Crawled : 14:20) - globenewswire.com
ATRX | $0.006 1724.82% 73K

Manufacturing

| Email alert Add to watchlist
mlr-1023 trial therapeutics diabetes

Atossa Therapeutics Issues Letter to Shareholders
Published: 2023-01-25 (Crawled : 14:00) - globenewswire.com
ATOS | $1.485 4.58% 4.38% 1.1M

Health Technology

| 97.01% | O: -0.83% H: 13.33% C: 11.84%
therapeutics

Inhibikase Therapeutics Announces Publication Demonstrating Potential for c-Abl as a Key Therapeutic Target in Parkinson's Disease and Related Disorders
Published: 2023-01-25 (Crawled : 14:00) - prnewswire.com
IKT | $1.57 14.6% 12.74% 78K

Health Technology

| -71.06% | O: 9.85% H: 15.78% C: -13.97%
c-abl disease parkinson's therapeutics potential publication

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
Published: 2023-01-25 (Crawled : 14:00) - allogene.com
ALLO | $3.365 -1.03% -1.04% 1.6M

Health Technology

| -57.56% | O: -2.14% H: 4.18% C: 2.83%
lung research preclinical therapeutics potential cancer

Inhibikase Therapeutics Announces FDA has Lifted the Full Clinical Hold on IkT-148009 in Parkinson's Disease
Published: 2023-01-25 (Crawled : 13:20) - prnewswire.com
IKT | $1.57 14.6% 12.74% 78K

Health Technology

| -71.06% | O: 9.85% H: 15.78% C: -13.97%
fda disease ikt-148009 lifted parkinson's therapeutics clinical hold

Vera Therapeutics Hosting a Key Opinion Leader Webinar on Atacicept for the Treatment IgA Nephropathy (IgAN)
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
VERA | $39.46 0.84% 0.84% 1.2M

Professional, Scientific, and T...

| 332.39% | O: -0.33% H: 1.1% C: -0.55%
treatment nephropathy therapeutics igan

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K

Health Technology

| -4.15% | O: -0.92% H: 1.41% C: 1.41%
SNY | News | $47.69 1.15% 1.13% 1.7M

Health Technology

| -2.97% | O: 0.39% H: 0.0% C: 0.0%
DNLI | $16.11 0.75% 0.74% 1.1M

Health Technology

| -46.8% | O: 0.3% H: 1.51% C: 1.45%
trial therapeutics sanofi sclerosis milestone phase 2 multiple sclerosis

Capricor Therapeutics Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
CAPR | $4.81 -2.63% -2.7% 480K

Health Technology

| 5.7% | O: -5.26% H: 7.64% C: 1.39%
cap-1002 ongoing label extension therapeutics duchenne positive results study

Jasper Therapeutics Announces Pricing of $90 Million Public Offering of Common Stock
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
JSPR | $22.0 -2.31% -2.36% 78K

| 1208.28% | O: -3.55% H: 22.7% C: 13.5%
offering therapeutics

Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
MRSN | $3.205 1.75% 1.72% 1.9M

Health Technology

| -51.58% | O: -0.6% H: 0.76% C: -0.46%
xmt-2056 trial therapeutics tumors her2- her2 phase 1

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer
Published: 2023-01-25 (Crawled : 13:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.0% 9.1M

Health Technology

| -11.08% | O: -0.68% H: 1.4% C: 1.4%
PLRX | $12.505 -0.75% -0.76% 240K

Health Technology

| -61.99% | O: -0.33% H: 5.82% C: 5.54%
therapeutics

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Published: 2023-01-25 (Crawled : 13:00) - biospace.com/
ATHE | $2.14 0.47% 0.47% 32K

Health Technology

| -45.1% | O: -2.06% H: 5.66% C: 2.63%
ath434 treatment system trial therapeutics phase 2

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates
Published: 2023-01-25 (Crawled : 12:00) - globenewswire.com
TNGX | $7.77 6.29% 5.92% 580K

| 9.13% | O: 0.0% H: 7.58% C: 0.84%
tng462 fda clearance drug application therapeutics

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis
Published: 2023-01-25 (Crawled : 12:00) - globenewswire.com
CDTX | News | $0.5141 0.04% 0.04% 1.9M

Health Technology

| -45.05% | O: 15.29% H: 21.5% C: 19.63%
treatment fda candidiasis approval therapeutics rezafungin candidemia

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering
Published: 2023-01-25 (Crawled : 03:00) - globenewswire.com
PLRX | $12.505 -0.75% -0.76% 240K

Health Technology